Aclaris Therapeutics (ACRS) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 84.8% versus a gain of 19.5%. Over five years, ACRS leads with a -79.8% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($501.1 million vs $500.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | CBIO |
|---|---|---|
| Share price | $3.40 | $13.49 |
| Market cap | $500.48M | $501.11M |
| 1-day change | -8.11% | -0.59% |
| YTD return | +12.96% | +13.74% |
| 1-year return | +84.78% | +19.49% |
| 5-year return | -79.77% | -93.19% |
| EPS (TTM) | $-0.58 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $27.41 |
| 52-week low | $1.74 | $8.72 |
| Distance from 52-week high | -48.48% | -50.78% |
| Average volume | 2.38M | 387.23K |
| Shares outstanding | 147.20M | 37.14M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed CBIO by 65.3 percentage points over the past year.
ACRS vs CBIO FAQ
Which is bigger, Aclaris Therapeutics or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $501.11M compared with $500.48M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or CBIO?
ACRS returned +84.78% over the past 12 months, compared with +19.49% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.